Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Burlington, Vermont 05401


Purpose:

The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) for treating patients with mild to moderate Ulcerative Colitis (UC). Even with the expanding choices of medication for UC, physicians and patients are still in search of highly effective and safe medications with minimal side effects. FMT has been approved for the treatment of a bacterial infection called Clostridium difficile. In this setting, FMT has been proven to be an effective and safe alternative therapy with zero reported serious adverse events from patients that have had this treatment. The providers that are conducting this study hypothesize that delivering microbes from a healthy human gut can help treat the damages caused by UC. This is done by "transplanting" fecal material, which contains a highly complex and dense community of healthy microbes, including bacteria, fungi and viruses. This collection of microbes is referred to as a microbiome. Preliminary studies suggest that alteration of the microbiome can help treat UC.


Criteria:

Inclusion Criteria: - Men or women 18-75 years of age. - Established diagnosis of ulcerative colitis (UC) with known involvement of the left colon - Mild to moderate disease defined as endoscopic evidence of disease with Mayo endoscopic sub-score 1 or 2 and total MAYO score ranging from 4-10. (The Mayo score ranges from 0 to 12, with higher scores indicating more severe disease. This score can be used for both initial evaluation and monitoring treatment response). - Patients may be on any class of IBD-related medication (excluding steroids) - Patients must be on stable medication regimen for at least 6 weeks prior to enrollment. - Ability to understand and willingness to sign informed consent document Exclusion Criteria: - Patient who are asymptomatic - Patients with severe, refractory disease (defined as Mayo scores of > 10, or endoscopic disease activity score of > 3) or patients with any other significant condition which, in the opinion of the investigator, could confound or interfere with evaluation of safety, tolerability of the investigational treatment or prevent compliance with the study protocol - Prior colectomy - Positive stool test for any of the following: Clostridium difficile by PCR, Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic E. coli by standard stool culture. - Use of the steroid medications (any formulation) in the prior 6 weeks to enrollment - Systemic antibiotic use within prior 6 weeks to enrollment - Regular probiotic supplement use within prior 48 hours to enrollment - Pregnancy or breastfeeding - Severe immunodeficiency, inherited or acquired (e.g. HIV, chemotherapy, or radiation therapy) - History of anaphylaxis (severe allergic reaction) - Documented allergy to fluoroquinolones, metronidazole - Life expectancy less than 12 months - Age less than 18 or greater than 75 years of age - History of esophageal or gastric motility disorders.


NCT ID:

NCT02390726


Primary Contact:

Principal Investigator
Peter L Moses, MD
The University of Vermont Medical Center


Backup Contact:

N/A


Location Contact:

Burlington, Vermont 05401
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.